Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Tables)

v3.22.0.1
Earnings (Loss) Per Common Share (Tables)
6 Months Ended
Dec. 31, 2021
Earnings (Loss) Per Common Share [Abstract]  
Schedule of Earnings (loss) Per Share, Basic and Diluted

Three Months Ended

Six Months Ended

December 31, 

December 31, 

    

2021

    

2020

2021

    

2020

Basic and diluted numerator:

Net loss attributable to iBio, Inc.

    

$

(11,920)

    

$

(8,129)

$

(20,859)

    

$

(15,662)

Preferred stock dividends – iBio CMO Preferred Tracking Stock

 

(22)

 

(65)

 

(88)

 

(131)

Net loss available to iBio, Inc. stockholders

$

(11,942)

$

(8,194)

$

(20,947)

$

(15,793)

 

 

 

 

Basic and diluted denominator:

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding

 

217,990

 

188,087

 

217,933

 

175,264

 

 

 

 

Per share amount

$

(0.05)

$

(0.04)

$

(0.10)

$

(0.09)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

December 31, 

    

2021

    

2020

(in thousands)

Stock options

 

14,943

 

4,251

Restricted stock units

 

768

 

349

Warrant issued under the Transaction

1,290

Shares excluded from the calculation of diluted loss per share

 

17,001

 

4,600